Britannia Life Sciences Inc. BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.21M | 1.84M | 5.80M | 5.70M | 5.12M |
| Total Depreciation and Amortization | 34.30K | 34.20K | 33.50K | 44.40K | 43.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.12M | -1.23M | -9.20M | -8.82M | -7.95M |
| Change in Net Operating Assets | -2.32M | -2.40M | -458.40K | -213.50K | -61.40K |
| Cash from Operations | -1.20M | -1.75M | -3.83M | -3.30M | -2.85M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.34M | -3.81M | 3.57M | 3.50M | 7.06M |
| Cash from Investing | 4.34M | -3.81M | 3.57M | 3.50M | 7.06M |
| Total Debt Issued | -- | -- | 958.60K | 909.10K | 1.68M |
| Total Debt Repaid | -79.40K | -84.60K | -1.09M | -1.12M | -1.11M |
| Issuance of Common Stock | 140.00K | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -186.20K | -737.90K | -1.29M |
| Cash from Financing | 43.60K | -61.40K | -226.40K | -672.20K | -508.60K |
| Foreign Exchange rate Adjustments | 16.30K | 300.00 | -10.70K | -11.80K | 18.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.20M | -5.63M | -488.80K | -479.40K | 3.72M |